Bio-Techne’s shares fell 10.2% following the quarter, as investor disappointment centered on continued organic revenue deceleration driven by emerging biotech weakness and cautious near-term outlook despite some pockets of growth and margin improvement.

• Organic revenue declined 2% for the quarter, weighed down by high single-digit declines in emerging biotech spending.
• Large pharma segment sustained low double-digit growth for its sixth consecutive quarter, while U.S. academia returned to low single-digit growth.
• Adjusted operating margin improved sequentially by 310 basis points to 34.2%, reflecting disciplined cost management.
• Order timing from two fast track cell therapy customers and a large OEM supply order created a 400 basis point headwind.
• China market continued positive organic growth for the fourth quarter in a row, driven by demand in biopharma and CRO sectors.